Long acting GLP-1 receptor agonist (injectable)
Albiglutide 30 mg injection every 2 weeks
ALBI_SC_30MG_Q2W
Related
- All doses pooled: Albiglutide injection
- Albiglutide 100 mg injection every 4 weeks
- Albiglutide 4 mg injection once weekly
- Albiglutide 15 mg injection once weekly
- Albiglutide 30 mg subcutaneous once weekly
- Albiglutide 15 mg injection every 2 weeks
- Albiglutide 50 mg injection every 2 weeks
- Albiglutide 50 mg injection every 4 weeks
- Albiglutide flexible dose injection once weekly
- Albiglutide 50 mg subcutaneous once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.98 (0.61 to 5.71) | 0.24 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.68 (0.66 to 3.93) | 0.65 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.62 (0.35 to 5.73) | 0.63 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.70 (0.64 to 4.15) | 0.47 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.59 (0.36 to 13.11) | 0.36 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.93 (0.05 to 16.72) | 0.45 |